AMRX: Amneal Pharmaceuticals, Inc. Stock

by  •  • Comments Off on AMRX: Amneal Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,797.90
Enterprise Value ($M) 5,318.08
Book Value ($M) -33.68
Book Value / Share -0.11
Price / Book -83.07
NCAV ($M) -1,981.36
NCAV / Share -6.39
Price / NCAV -1.41

Profitability (mra)
Return on Invested Capital (ROIC) -0.07
Return on Assets (ROA) -0.05
Return on Equity (ROE) -0.96

Liquidity (mrq)
Quick Ratio 0.84
Current Ratio 1.38

Balance Sheet (mrq) ($M)
Current Assets 1,513.29
Assets 3,460.98
Liabilities 3,494.66
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
1 day ago 13G/A Mahesh Akram 8.80 -11.61
10-31 13D/A Patel Chirag K. 7.10 0.00
05-13 13D/A Patel Tushar Bhikhubhai 17.40 0.00
04-24 13G/A Fosun International Ltd 3.00 -50.02
02-13 13G/A Vanguard Group Inc 4.45 4.55
01-03 13D/A Patel Gautam 0.07 -94.02
2023-11-08 13D/A Patel Chintu 8.30 0.00
2023-11-08 13D/A Patel Dipan 8.80 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-14 195,910 1,235,203 15.86
2024-11-13 166,040 887,608 18.71
2024-11-12 244,533 1,210,395 20.20
2024-11-11 173,092 2,063,790 8.39

(click for more detail)

Similar Companies
AMGN – Amgen Inc. AMLX – Amylyx Pharmaceuticals, Inc.
AMPH – Amphastar Pharmaceuticals, Inc. ANAB – AnaptysBio, Inc.
ANNX – Annexon, Inc.


Financial data and stock pages provided by
Fintel.io